Development and biological function of the female gonads and genitalia in IGF-I deficiency Laron syndrome as a model
Retatrutide is expected to receive FDA approval in late 2027 or early 2028, assuming Phase 3 trials are successful
The rise of GLP1 medications has become one of the "strongest accelerators of these behaviors," he adds
Its approved for weight loss in adults with obesity or those who are overweight and have a weight-related comorbidity like high blood pressure, type 2 diabetes, and dyslipidemia (unhealthy levels of cholesterol and fat in the blood)
It influences matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), stimulating both the synthesis and the controlled breakdown of collagen and glycosaminoglycans
Burkhoff D, Maurer MS, Joseph SM, et al